 | Up a level |
Peters, Solange; Danson, Sarah; Ejedepang, Dunson; Dafni, Urania; Hasan, Baktiar; Radcliffe, Hoi-Shen; Bustin, Frederique; Crequit, Jacky; Coate, Linda; Guillot, Monica; Surmont, Veerle; Rauch, Daniel; Rudzki, Jakob; O'Mahony, Deirdre; Barneto Aranda, Isidoro; Scherz, Amina; Tsourti, Zoi; Roschitzki-Voser, Heidi; Pochesci, Alessia; Demonty, Gaston; ... (2021). Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung cancer, 161, pp. 76-85. Elsevier 10.1016/j.lungcan.2021.09.002
Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; ... (2020). A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of thoracic oncology, 15(10), pp. 1647-1656. Elsevier 10.1016/j.jtho.2020.06.011
Dziadziuszko, Rafal; Smit, Egbert F; Dafni, Urania; Wolf, Juergen; Wasąg, Bartosz; Biernat, Wojciech; Finn, Stephen P; Kammler, Roswitha; Tsourti, Zoi; Rabaglio, Manuela; Ruepp, Barbara; Roschitzki-Voser, Heidi; Stahel, Rolf A; Felip, Enriqueta; Peters, Solange (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of thoracic oncology, 14(6), pp. 1086-1094. Elsevier 10.1016/j.jtho.2019.02.017
Rosell, Rafael; Dafni, Urania; Felip, E; Curioni-Fontecedro, A; Gautschi, O; Peters, S; Massuti, B; Palmero, R; Aix, SP; Carcereny, E; Früh, M; Pless, M; Popat, S; Kotsakis, A; Cuffe, S; Bidoli, P; Favaretto, A; Froesch, P; Reguart, N; Puente, J; ... (2017). Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. The lancet. Respiratory medicine, 5(5), pp. 435-444. Elsevier 10.1016/S2213-2600(17)30129-7
Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; ... (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of thoracic oncology, 12(4), pp. 752-762. Elsevier 10.1016/j.jtho.2016.12.017
Procter, Marion; Suter, Thomas M; de Azambuja, Evandro; Dafni, Urania; van Dooren, Veerle; Muehlbauer, Susanne; Climent, Miguel Angel; Rechberger, Ernst; Liu, Walter Tsang-Wu; Toi, Mazakasu; Coombes, R Charles; Dodwell, David; Pagani, Olivia; Madrid, Jorge; Hall, Marcia; Chen, Shin-Cheh; Focan, Christian; Muschol, Michael; van Veldhuisen, Dirk J and Piccart-Gebhart, Martine J (2010). Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. Journal of clinical oncology, 28(21), pp. 3422-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2009.26.0463
